Abstract:Autoimmune bullous skin disorders are rare but meaningful chronic inflammatory diseases, many of which had a poor or devastating prognosis prior to the advent of immunosuppressive drugs such as systemic corticosteroids, which down-regulate the immune pathogenesis in these disorders. Glucocorticoids and adjuvant immunosuppressive drugs have been of major benefit for the fast control of most of these disorders, but their long-term use is limited by major side effects such as blood cytopenia, osteoporosis, diabetes mellitus, hypertension, and gastrointestinal ulcers. In recent years, major efforts were made to identify key elements in the pathogenesis of autoimmune bullous disorders, leading to the identification of their autoantigens, which are mainly located in desmosomes (pemphigus) and the basement membrane zone (pemphigoids). In the majority of cases, immunoglobulin G, and to a lesser extent, immunoglobulin A autoantibodies directed against distinct cutaneous adhesion molecules are directly responsible for the loss of cell-cell and cell-basement membrane adhesion, which is clinically related to the formation of blisters and/or erosions of the skin and mucous membranes. We describe and discuss novel therapeutic strategies that directly interfere with the production and regulation of pathogenic autoantibodies (rituximab), their catabolism (intravenous immunoglobulins), and their presence in the circulation and extravascular tissues such as the skin (immunoadsorption), leading to a significant amelioration of disease. Moreover, we show that these novel therapies have pleiotropic effects on various proinflammatory cells and cytokines. Recent studies in bullous pemphigoid suggest that targeting of immunoglobulin E autoantibodies (omalizumab) may be also beneficial. In summary, the introduction of targeted therapies in pemphigus and pemphigoid holds major promise because of the high efficacy and fewer side effects compared with conventional global immunosuppressive therapy.

Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases—Implications for Therapeutic Approaches

B Cells in Autoimmune Diseases

Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment

B Cell Activation and Autoantibody Production in Autoimmune Diseases.

From neglect to spotlight: the underappreciated role of B cells in cutaneous inflammatory diseases

T cell pathology in skin inflammation

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

Aberrant inflammasome activation as a driving force of human autoimmune skin disease

Immunopathology and Immunotherapy of Inflammatory Skin Diseases

Immune cells in pemphigus vulgaris and bullous Pemphigoid: From pathogenic roles to targeting therapies

B cell-targeted therapies in autoimmunity: rationale and progress

The role of B cells in systemic sclerosis

Role of B-Cell in the Pathogenesis of Systemic Sclerosis

[Cell adhesion molecules and extracellular matrix components as target structures of autoimmunity]

[Cellular adhesion molecules and components of the extracellular matrix as target structures of autoimmunity]

The role of B lymphocyte in the pathogenesis of psoriasis

Analysis of T cell repertoires of CD45RO CD4 T cells in cohorts of patients with bullous pemphigoid: A pilot study

Targeted Therapies for Autoimmune Bullous Diseases: Current Status

T Cell/B Cell Collaboration and Autoimmunity: An Intimate Relationship

B-Cell Depletion and Repopulation in Autoimmune Diseases

The Multiple Roles of B Cells in the Pathogenesis of Sjögren’s Syndrome